

#3
RECEIVED

JUL 20 2001

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Application of:

JUL 19 2001 JONES et al.

Serial No.: 09/828,276

Dated: April 6, 2001

Art Unit: 1623

Examiner: Not yet assigned

Atty. Docket No.: 00-721

ADENOSINE CYCLE KETALS: NOVEL
ADENOSINE ANALOGUES FOR
CARDIOVASCULAR
PHARMACOTHERAPY

Pittsburgh, Pennsylvania 15230

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

This Information Disclosure Statement is filed in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98. The items listed on the enclosed Form PTO-1449 may be deemed to be pertinent to the above-identified application and are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being

MAILED

deposited with the United States Postal Service on July 18, 2001 with sufficient postage as first-class mail in an envelope addressed to the: Commissioner for Patents, Washington, D.C. 20231.

FACSIMILE

transmitted by facsimile on [date] to the U.S. Patent and Trademark Office.

Type Signature Name

Tracey A. Cochran

Tracey Cochran

(Signature of person mailing paper or fee)

(Signature of person mailing paper or fee)

1. Enclosed is PTO Form 1449 (and a duplicate thereof).
2. Items listed on the enclosed Form PTO-1449 are not in the English language.
 - For each of the following items, an English-language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed.
 - For each of the following items, a concise explanation of that item is incorporated in the specification of the above-identified application:
 - For each of the following items, a corresponding U.S. or other English-language patent is enclosed. Please consider the U.S. or other English-language patents in accordance with the procedure set forth in MPEP § 609:
3. **Submission in Accordance with 37 CFR § 1.97(b).**
This Information Disclosure Statement is being filed
 - With the application;
 - Within three months of the filing date of a national application;
 - Within three months of the date of entry of the national stage in an international application; or
 - Before the mailing date of a first Office Action on the merits,

and NO FEE is due for consideration of this Information Disclosure Statement.

4. **Fee Payment Being Made.**
 - Enclosed
 - \$180.00 fee for submission under 37 CFR § 1.97(c).
 - \$180.00 fee for submission under 37 CFR § 1.97(d).
 - A check in the amount of \$[Amount] to cover the fee payment is enclosed.
 - Charge the fee to Deposit Account No. 18-0582. A duplicate copy of this communication is attached.

- The Director is hereby authorized to charge payment of any additional fees associated with this Information Disclosure Statement or credit any overpayment to Deposit Account No. 18-0582. A duplicate copy of this communication is enclosed.

Respectfully submitted,



Dated: July 18, 2001

Robert D. Kuckler
Reg. No. 45,908

REED SMITH LLP
P.O. Box 488
Pittsburgh, PA 15230
(412) 288-4598

Attorney for Applicants